<DOC>
	<DOCNO>NCT00003253</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Some patient may develop resistance chemotherapy drug . PURPOSE : Phase II trial determine reliability test measure drug resistance paclitaxel patient metastatic breast cancer .</brief_summary>
	<brief_title>Evaluation Drug Resistance Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate proportion patient extreme , intermediate , low drug resistance paclitaxel use Extreme Drug Resistance ( EDR ) Assay patient previously treat metastatic breast cancer . II . Assess response paclitaxel therapy patient undergone pretreatment EDR assay . III . Assess time tumor progression paclitaxel therapy patient undergone pretreatment EDR assay . IV . Determine prospectively predictive value EDR assay relative clinical outcome correlate assay result clinical tumor response time tumor progression paclitaxel therapy patient . OUTLINE : This open label , single arm , blind study . Patients ' tumor tissue sample collect excisional biopsy , core biopsy , malignant fluid aspiration , test Extreme Drug Resistance ( EDR ) Assay determine probability drug resistance paclitaxel . After successful completion EDR assay ( approximately 7 day ) , patient receive paclitaxel intravenous infusion 1-3 hour ; treatment repeat every 3 week . Treatment continue document evidence tumor progression unacceptable toxicity . Patients ' clinical response paclitaxel therapy compare response predict EDR assay . PROJECTED ACCRUAL : 100 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Metastatic breast cancer accessible biopsy aspiration Bidimensionally measurable disease least one diameter great 1 cm document xray photograph , palpable lesion No brain metastases carcinomatous meningitis Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Male female Menopausal status : Not specify Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL SGOT great 3 time upper limit normal ( ULN ) ( great 5 time ULN metastatic liver ) Renal : Creatinine great 2.0 mg/dL Calcium great 12 mg/dL Cardiovascular : No myocardial infarction within 3 month prior study No unstable angina symptomatic congestive heart failure Other : No active uncontrolled infection Not HIV positive No psychoses Not pregnant nursing Effective contraception require fertile woman No second malignancy within past 5 year except : Adequately treat basal squamous cell carcinoma skin In situ cancer cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Prior paclitaxel permit patient diseasefree interval great 1 year Prior taxotere permit Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>